恩度联合顺铂胸腔灌注治疗肺癌合并恶性胸腔积液疗效的meta分析  

The efficacy of Endo combined with cisplatin in the treatment of lung cancer complicated with malignant pleural effusion:A meta-analysis

作　　者：赵哲[1,2] 穆培娟 张冬[1] Zhao Zhe;Mu Peijuan;Zhang Dong(Department of Respiratory and Critical Diseases,the First Affiliated Hospital of Baotou Medical College,Baotou 014010,China;Baotou Medical College of Inner Mongolia University of Science&Technology,Baotou 014040,China)

机构地区：[1]内蒙古科技大学包头医学院第一附属医院呼吸与危重症科,内蒙古包头014010 [2]内蒙古科技大学包头医学院,内蒙古包头014040

出　　处：《临床荟萃》2023年第5期399-404,共6页Clinical Focus

基　　金：包头市卫生健康科技计划项目——miR-17-5p调控PKD2对肺腺癌生物学行为的影响及机制研究(wsjkkj009)。

摘　　要：目的系统评价恩度联合顺铂胸腔灌注治疗肺癌合并恶性胸腔积液的有效性和安全性。方法计算机检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、Pubmed、The Cochrane Library、Web of Science、Proquest和Embase,筛选出有关恩度联合顺铂胸腔内灌注治疗肺癌合并恶性胸腔积液随机对照试验,通过RevMan 5.3软件进行meta分析,计算相对危险度(RR)及95%可信区间(CI),采用Stata 15.0软件进行Egger检验。结果共纳入12项随机对照研究,共728例患者。对照组为单顺铂药物治疗共363例,试验组为恩度联合顺铂治疗共365例。Meta分析显示,与对照组相比,试验组的总有效率[RR=1.62,95%CI(1.45~1.81);Z=8.48,P<0.05]和生活质量改善率[RR=1.68,95%CI(1.44~1.96);Z=6.60,P<0.05]均高于对照组,但两组在主要不良反应如:白细胞减少、血小板减少、恶性呕吐方面比较,差异无统计学意义(P>0.05)。结论恩度联合顺铂胸腔内灌注治疗肺癌合并恶性胸腔积液的效果优于顺铂单药组,联合治疗对比顺铂单药治疗能提高总有效率,患者的生活质量有所改善,且总体不增加不良反应发生率。Objective To systematically evaluate the efficacy and safety of Endo combined with cisplatin in the treatment of lung cancer with malignant pleural effusion.Methods We conducted a Computer search in CNKI databases,WanFang Data,the Chongqing VIP Chinese Science and Technology Periodical Database(VIP),Chinese Biomedical Literature Database(CBM),Pubmed,Cochrane Library,Web of Science,Proquest,and Embase to screen the randomized controlled trial regarding endostar plus intrapleural cisplatin for lung cancer with malignant pleural effusion.We performed a meta-analysis using Revman 5.3 software to calculate the relative risk(RR)and 95%confidence interval(CI),and performed the Egger test using Stata 15.0 software.Results A total of 2 randomized controlled studies were included representing 728 patients who consisted cisplatin single drug group(control group,n=363)and endu combined with cisplatin group(experimental group,n=365).Meta analysis showed that the total effective rate(RR=1.62,95%CI[1.45-1.81];Z=8.48,P<0.05)and the improvement rate of quality of life(RR=1.68,95%CI[1.44-1.96];Z=6.60,P<0.05)in the experimental group were higher when compared with the control group,but there was no significant difference in the main adverse reactions such as leucopenia,thrombocytopenia and malignant vomiting(P>0.05)between groups.Conclusion The combination endostar with intrapleural cisplatin is better than cisplatin single drug in the treatment of lung cancer with malignant pleural effusion,which can improve the total effective rate,improve the quality of life of patients,and did not increase the incidence of adverse reactions as a whole.

关 键 词：肺癌 恩度 顺铂 恶性胸腔积液 META分析 

分 类 号：R563.3[医药卫生—呼吸系统]